



January 4, 2021

PeptiDream Inc.

<https://www.peptidream.com>

Ticker Code : 4587 TSE First Section

PeptiDream Announces the Merger of Kleo Pharmaceuticals with Biohaven

KANAGAWA, JAPAN – January 4th, 2021 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TSE:4587) announced today that Biohaven Pharmaceuticals Holding Company Ltd. (“Biohaven”)(NYSE:BHVN), a public clinical stage biopharmaceutical company, has entered into a merger agreement with PeptiDream’s strategic partner Kleo Pharmaceuticals (“Kleo”), to take over full control of Kleo, the Yale-Spiegel Lab’s intellectual property, and all of Kleo’s discovery and development programs, including the PeptiDream-partnered CD38-ARM programs.

[Comment from Patrick C. Reid PhD, President & CEO of PeptiDream]

“It has been a challenging year for Kleo, from both a fund raising and clinical development progress perspective, in light of the corona virus pandemic, however, PeptiDream is very happy to announce the takeover of Kleo and the associated Yale-Spiegel Lab’s intellectual property by Biohaven, a company with vast clinical development expertise and a major shareholder in Kleo, and we greatly look forward to working with the Biohaven clinical development team on progressing the CD38 programs into the clinic once the corona virus situation stabilizes.”

[Comment from Vlad Coric MD, CEO of Biohaven Pharmaceuticals]

“Through this acquisition of the Yale-Spiegel Lab’s intellectual property regarding novel next-generation, bispecific compounds designed to emulate or enhance the activity of biologics (formerly Kleo Pharmaceuticals), Biohaven is excited to directly establish a close working relationship with PeptiDream to advance this immune-targeting platform. This important collaboration will leverage PeptiDream’s industry leading peptide-based drug discovery platform will allow us to rapidly progress small molecule-based therapeutics modulating the immune system. Our clinical development team looks forward to working closely with the PeptiDream team to advance new therapeutics to patients across a variety of therapeutic indications.”

<About PeptiDream Inc.>

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.

Enquiries:**PeptiDream Inc.**

Mie Yamazaki IR & Public Affairs - (Kanagawa)

EMAIL: m-yamazaki@peptidream.com